TY  - JOUR
A1  - Dannewitz, Bettina
A1  - Sommerer, Claudia
A1  - Stölzel, Peggy
A1  - Baid‐Agrawal, Seema
A1  - Nadal, Jennifer
A1  - Bärthlein, Barbara
A1  - Wanner, Christoph
A1  - Eckardt, Kai‐Uwe
A1  - Zeier, Martin
A1  - Schlagenhauf, Ulrich
A1  - Krane, Vera
A1  - Jockel‐Schneider, Yvonne
T1  - Status of periodontal health in German patients suffering from chronic kidney disease—Data from the GCKD study
JF  - Journal of Clinical Periodontology
N2  - Aim
To assess the prevalence and severity of periodontitis in patients with moderate chronic kidney disease (CKD) and comparing the results with the self‐reported periodontitis awareness of the study subjects.

Material and methods
The periodontal status of 270 patients with moderate CKD randomly selected from a cohort of 5,217 subjects participating in the prospective observational German Chronic Kidney Disease (GCKD) project was analysed by recording bleeding on probing (BOP), probing pocket depth (PPD) and clinical attachment level (CAL). Furthermore, the awareness of the study subjects of their periodontal conditions was evaluated by a self‐reported questionnaire.

Results
24.4% of the CKD study patients showed no or only mild signs of periodontal disease, 47.6% displayed moderate and 27% severe periodontitis. Questionnaire data revealed that 62.3% of the study subjects with severe periodontitis were not aware of the presence of the disease, 44.4% denied having received any systematic periodontal therapy so far, although 50% of them indicated to visit their dentist regularly for professional tooth cleanings.

Conclusion
While the clinical study data confirm an increased prevalence of periodontitis in CKD patients, their self‐reported awareness of periodontitis was low.
KW  - chronic kidney disease
KW  - observational cohort study
KW  - periodontitis
KW  - risk factors
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-217821
VL  - 47
IS  - 1
SP  - 19
EP  - 29
ER  - 
TY  - JOUR
A1  - Busch, Martin
A1  - Nadal, Jennifer
A1  - Schmid, Matthias
A1  - Paul, Katharina
A1  - Titze, Stephanie
A1  - Hübner, Silvia
A1  - Köttgen, Anna
A1  - Schultheiss, Ulla T.
A1  - Baid-Agrawal, Seema
A1  - Lorenzen, Johan
A1  - Schlieper, Georg
A1  - Sommerer, Claudia
A1  - Krane, Vera
A1  - Hilge, Robert
A1  - Kielstein, Jan T.
A1  - Kronenberg, Florian
A1  - Wanner, Christoph
A1  - Eckardt, Kai-Uwe
A1  - Wolf, Gunter
T1  - Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort
JF  - BMC Nephrology
N2  - Background

Diabetes mellitus (DM) is the leading cause of end-stage renal disease. Little is known about practice patterns of anti-diabetic therapy in the presence of chronic kidney disease (CKD) and correlates with glycaemic control. We therefore aimed to analyze current antidiabetic treatment and correlates of metabolic control in a large contemporary prospective cohort of patients with diabetes and CKD.

Methods

The German Chronic Kidney Disease (GCKD) study enrolled 5217 patients aged 18–74 years with an estimated glomerular filtration rate (eGFR) between 30–60 mL/min/1.73 m2 or proteinuria >0.5 g/d. The use of diet prescription, oral anti-diabetic medication, and insulin was assessed at baseline. HbA1c, measured centrally, was the main outcome measure.

Results

At baseline, DM was present in 1842 patients (35 %) and the median HbA1C was 7.0 % (25th–75th percentile: 6.8–7.9 %), equalling 53 mmol/mol (51, 63); 24.2 % of patients received dietary treatment only, 25.5 % oral antidiabetic drugs but not insulin, 8.4 % oral antidiabetic drugs with insulin, and 41.8 % insulin alone. Metformin was used by 18.8 %. Factors associated with an HbA1C level >7.0 % (53 mmol/mol) were higher BMI (OR = 1.04 per increase of 1 kg/m2, 95 % CI 1.02–1.06), hemoglobin (OR = 1.11 per increase of 1 g/dL, 95 % CI 1.04–1.18), treatment with insulin alone (OR = 5.63, 95 % CI 4.26–7.45) or in combination with oral antidiabetic agents (OR = 4.23, 95 % CI 2.77–6.46) but not monotherapy with metformin, DPP-4 inhibitors, or glinides.

Conclusions

Within the GCKD cohort of patients with CKD stage 3 or overt proteinuria, antidiabetic treatment patterns were highly variable with a remarkably high proportion of more than 50 % receiving insulin-based therapies. Metabolic control was overall satisfactory, but insulin use was associated with higher HbA1C levels.
KW  - Chronic kidney disease
KW  - Glycaemic control
KW  - Hemoglobin A1C
KW  - Insulin therapy
KW  - Oral antidiabetic drugs
KW  - Diabetes mellitus
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164687
VL  - 17
IS  - 59
ER  -